Study on metabolic pathway of mild cognitive impairment in type 2 diabetes patients

Abstract

Background The Montreal Cognitive Assessment Scale (MoCA) survey was used to examine the risk factors contributing to the development of mild cognitiveMethods impairment (MCI) in patients with type 2 diabetes mellitus (T2DM) in combination with clinical practice, the Montreal Cognitive, The Assessment Scale (MoCA) was used to assess cognitive function. Based on the MoCA scale scores, subjects were included in a total of 147 cases in the type 2 diabetes mellitus with mild cognitive impairment group (T2DM-MCI group) (MoCA score < 26) and a total of 53 cases in the group with type 2 diabetes mellitus group with normal cognitive function (T2DM-NCI group) (MoCA score ≥ 26 points). While venous serum samples were collected from the patients, the metabolic data were analyzed using ultra-performance liquid chromatography-mass spectrometry (UPLC-Q/TOF-MS) for the T2DM-MCI and T2DM-NCI groups to identify the metabolites with differential expression to analyze their related metabolic pathways between the two groups and to investigate the metabolic characteristics of MCI in T2DM patients.Results The results of comparing general clinical data between the T2DM-MCI group and the T2DM-NCI group showed that there were significant differences in the training and age of the patients.Conclusions Patients with type 2 diabetes mellitus with advanced age, short educational period, high D-dimer level and high glycosylated hemoglobin are more likely to have mild cognitive impairment. Caffeine metabolism and sphingolipid metabolism were the main metabolic pathways, and the abnormalities of their metabolic pathways may lead to the occurrence and development of cognitive dysfunction in T2DM patients.